Our previous work demonstrated that the FLT3 inhibitors midostaurin and gilteritinib can downregulate Mcl-1 and synergy with anti-F L T 3 mutation-positive AML activity with ABT-199 [27]. This evidence concerns the gene FLT3 and acute myeloid leukemia.